Skip to main content
Fabrice Barlesi on Muck Rack

Fabrice Barlesi

As seen in: Nature, Wiley Online Library, Therapeutic Advances in Medical Oncology, Medscape, Cell Press, The Lancet, medRxiv, European Respiratory Journal, Targeted Oncology, International Journal of Radiation Oncology*Biology*Physics and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Fabrice

Contact Fabrice, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Multimodal profiling for prediction of primary resistance to anti–PD-(L)1 therapy in advanced non-small-cell lung cancer: the prospective PIONeeR biomarkers study

|
By Fabrice Barlesi, Fréderic Vély, Florence Monville
| medRxiv
The authors have declared no competing interest. This work benefited from a government grant handled by the French National Research Agency (ANR) as part of the France 2030 investment plan, under the reference ANR-17-RHUS-0007.
Open in Who Shared Issue with article?

Mapping the antibody-drug‐conjugates landscape in non-small cell lung cancer: Where are we and where are we going?

|
By Claudia Parisi, Fabrice Barlesi, David Planchard
| Wiley Online Library Verified
Open in Who Shared Issue with article?

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study

|
By David Planchard, Nathalie Cozic, Maria Fernanda Mosele, Noemie Corcos, Loic Le Bescond, Yoann Pradat, Maria Rosa Ghigna, Ghada Nachabeh, Alexia Alfaro, Cyril Catelain, Bastien Job, Fathia Mami-Chouaib, Severine Badel, Stephanie Corgnac, Françoise Farace, Marianne Oulhen, Patricia L. Kannouche, Nathalie Droin, Marie Wislez, Christos Chouaid, Hubert Curcio, Sophie Cousin Verified, Celine Mascaux, Jacques Cadranel, Margaux Geier, Rasha Cheikh-Hussin, Pierre Guyader, Nicholas Signolle, Karine Godefroy, Hugues Talbot, Maria Vakalopoulou, Stergios Christodoulidis, Elsa Bernard, Yves Akoli Koudou, Valerie Camara, Abdelhafidh Belarkemi, alexis klein, Jean Philippe Morretton, Philip East, Rachel Chiaverelli, Ricardo Zwirtes, Stefan Michiels, Fabrice Barlesi, Fabrice André, Guillaume Montagnac, Barbara Pistilli
| Cell Press Verified
Keywords ADC Dato-DXd mechanism of action response resistance NSCLC TROP2 internalization Introduction In 2022, lung cancer was the most frequently diagnosed cancer, with about 2.5 million new cases, and the leading cause of cancer death, with 1.8 million deaths worldwide.1 Several targeting therapies have been developed and approved over the past years for the treatment of metastatic lung cancer, particularly for non-small cell lung cancer (NSCLC); however, only 35%–40% of patients with...
Open in Who Shared Issue with article?
See all 30 licensed articles (31 Total)